Citadel Advisors’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-386,545
| Closed | -$12.9M | – | 14756 |
|
|
2026
Q1 | $12.9M | Buy |
386,545
+77,715
| +25% | +$3.05M | ﹤0.01% | 2881 |
|
|
2025
Q4 | $14.3M | Sell |
308,830
-141,296
| -31% | -$7.75M | ﹤0.01% | 2762 |
|
|
2025
Q3 | $30.4M | Sell |
450,126
-1,055,035
| -70% | -$78.2M | ﹤0.01% | 1861 |
|
|
2025
Q2 | $126M | Sell |
1,505,161
-70,883
| -4% | -$5.31M | 0.02% | 621 |
|
|
2025
Q1 | $113M | Buy |
1,576,044
+603,634
| +62% | +$29.4M | 0.02% | 629 |
|
|
2024
Q4 | $43.7M | Buy |
972,410
+950,670
| +4,373% | +$49.3M | 0.01% | 1399 |
|
|
2024
Q3 | $1.1M | Buy |
21,740
+13,613
| +168% | +$652K | ﹤0.01% | 6691 |
|
|
2024
Q2 | $332K | Buy |
+8,127
| New | +$344K | ﹤0.01% | 8933 |
|
|
2023
Q4 | – | Sell |
-40,625
| Closed | -$1.16M | – | 15167 |
|
|
2023
Q3 | $1.2M | Buy |
+40,625
| New | +$246K | ﹤0.01% | 6201 |
|
|
2022
Q3 | – | Sell |
-19,687
| Closed | -$55K | – | 13528 |
|
|
2022
Q2 | $55K | Buy |
19,687
+10,045
| +104% | +$27.8K | ﹤0.01% | 11872 |
|
|
2022
Q1 | $32K | Sell |
9,642
-350
| -4% | -$1.81K | ﹤0.01% | 13073 |
|
|
2021
Q4 | $61K | Sell |
9,992
-538
| -5% | -$5.64K | ﹤0.01% | 13134 |
|
|
2021
Q3 | $146K | Buy |
10,530
+871
| +9% | +$12.1K | ﹤0.01% | 12411 |
|
|
2021
Q2 | $165K | Buy |
9,659
+5,466
| +130% | +$92.4K | ﹤0.01% | 12395 |
|
|
2021
Q1 | $79K | Buy |
4,193
+2,837
| +209% | +$91.4K | ﹤0.01% | 12636 |
|
|
2020
Q4 | $39K | Buy |
1,356
+382
| +39% | +$11K | ﹤0.01% | 10658 |
|
|
2020
Q3 | $37K | Buy |
+974
| New | +$28.5K | ﹤0.01% | 9702 |
|
|
2019
Q2 | – | Sell |
-1,195
| Closed | -$37K | – | 9785 |
|
|
2019
Q1 | $37K | Buy |
+1,195
| New | +$31.8K | ﹤0.01% | 8930 |
|
|
2018
Q3 | – | Sell |
-862
| Closed | -$30K | – | 9648 |
|
|
2018
Q2 | $30K | Buy |
+862
| New | +$25.3K | ﹤0.01% | 8567 |
|
|
2017
Q4 | – | Sell |
-365
| Closed | -$14K | – | 8407 |
|
|
2017
Q3 | $14K | Buy |
+365
| New | +$14.4K | ﹤0.01% | 7414 |
|
|
2017
Q2 | – | Sell |
-327
| Closed | -$17K | – | 8014 |
|
|
2017
Q1 | $17K | Buy |
+327
| New | +$19.3K | ﹤0.01% | 7289 |
|
|
2016
Q4 | – | Sell |
-317
| Closed | -$23K | – | 7794 |
|
|
2016
Q3 | $23K | Buy |
+317
| New | +$24K | ﹤0.01% | 7009 |
|
|
2015
Q3 | – | Sell |
-140
| Closed | -$30K | – | 9200 |
|
|
2015
Q2 | $30K | Buy |
+140
| New | +$53.8K | ﹤0.01% | 7964 |
|
Citadel Advisors's SLNO Position: Q2 2026 in Review
Citadel Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 386,545 shares — an estimated $12.9M sold.
Citadel Advisors first reported a position in SLNO in Q2 2015 and held it in 23 quarters. The position peaked at $126M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Citadel Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 386,545 Soleno Therapeutics shares in Q2 2026, an estimated $12.9M.
- Citadel Advisors first reported a position in Soleno Therapeutics in Q2 2015 and held it in 23 quarters.
- Citadel Advisors's Soleno Therapeutics position peaked at $126M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.